Market Alert: Strong Breakout Setup Emerging in ASX 200 Utilities Sector
Starpharma (ASX: SPL), a pioneer in dendrimer-based nanomedicine, continues to advance its strategic priorities across drug delivery, radiopharmaceuticals, and global consumer healthcare. The company reported progress in its DEP® SN38 and cabazitaxel partnering initiatives, backed by encouraging FDA feedback. A key highlight was the one-year milestone of its dynamic collaboration with Medicxi-formed Petalion Therapeutics. The company also launched its "Star Navigator" initiative and participated in BIO-Europe, securing over 30 meetings to promote its DEP® platform.
Commercially, Starpharma launched VivaGel® BV in Saudi Arabia and the UAE, and initiated a Viraleze™ campaign in the UK. Financially, it ended the March 2025 quarter with AU$17.2 million in cash, with reduced quarterly outflows of AU$2.7 million. The leadership remains committed to strategic execution, operational efficiency, and value creation via partnerships, especially in radiotheranostics, while building sustainable revenue from its marketed products
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
May 01, 2025
May 01, 2025
May 01, 2025
May 01, 2025
May 01, 2025
May 01, 2025
May 01, 2025
May 01, 2025
May 01, 2025
Apr 30, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
